{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:06:12Z","timestamp":1790795172314,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.nmd.2021.08.009","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T02:40:46Z","timestamp":1635820846000},"page":"998-1003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Spinal muscular atrophy: from rags to riches"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-5365","authenticated-orcid":false,"given":"Eugenio","family":"Mercuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2021.08.009_bib0001","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF01776636","article-title":"Zwei fruhinfantilehereditare Falle von progressive r Muskelatrophie unter dem bilde der dystrophie, aber auf neurotisscher grundlage","volume":"22","author":"Werdnig","year":"1891","journal-title":"Arch Psychiatr Nervenkr (1970)"},{"key":"10.1016\/j.nmd.2021.08.009_bib0002","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF01668496","article-title":"Uber chronische spinale Muskelatrophie im Kindersalter auf familiarer basis","volume":"3","author":"Hoffmann","year":"1893","journal-title":"Deut Zeitsch Nervenheilkd"},{"key":"10.1016\/j.nmd.2021.08.009_bib0003","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/archneurpsyc.1956.02330230050005","article-title":"Heredofamilial juvenile muscular atrophy simulating muscular dystrophy","volume":"75","author":"Kugelberg","year":"1956","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"10.1016\/j.nmd.2021.08.009_bib0004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nmd.2008.10.004","article-title":"Ramblings in the history of spinal muscular atrophy","volume":"19","author":"Dubowitz","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0005","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/brain\/87.4.707","article-title":"Infantile muscular atrophy. A prospective study with particular reference to a slowly progressive variety","volume":"87","author":"Dubowitz","year":"1964","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2021.08.009_bib0006","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/344540a0","article-title":"Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3","volume":"344","author":"Brzustowicz","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2021.08.009_bib0007","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/344767a0","article-title":"Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q","volume":"344","author":"Melki","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2021.08.009_bib0008","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.nmd.2021.08.009_bib0009","series-title":"2nd international congress on neurogenetics and neuro-opthalmology","first-page":"17","article-title":"Hereditary proximal spinal muscularatrophy: single or multiple genes?","author":"Dubowitz","year":"1969"},{"key":"10.1016\/j.nmd.2021.08.009_bib0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0960-8966(91)90106-3","article-title":"Clinical and genetic heterogeneity in spinal muscular atrophy\u2013the multiple allele model","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0011","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0960-8966(91)90051-S","article-title":"Chaos in classification of the spinal muscular atrophies of childhood","volume":"1","author":"Dubowitz","year":"1991","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0960-8966(94)00075-K","article-title":"Chaos in the classification of SMA: a possible resolution","volume":"5","author":"Dubowitz","year":"1995","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0013","first-page":"423","article-title":"International SMA consortium meeting","volume":"2","author":"Munsat","year":"1992","journal-title":"26-28 June 1992, Bonn, Germany). Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0014","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","article-title":"209th ENMC international workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7-9 November 2014","volume":"25","author":"Finkel","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0015","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0016","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nmd.2017.09.015","article-title":"Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy","volume":"28","author":"De Sanctis","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0017","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","article-title":"Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients","volume":"146","author":"Zerres","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2021.08.009_bib0018","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1090-3798(99)80015-4","article-title":"Prenatal onset spinal muscular atrophy","volume":"3","author":"MacLeod","year":"1999","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0019","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1090-3798(99)80012-9","article-title":"Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype","volume":"3","author":"Dubowitz","year":"1999","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0020","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0021","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldkotter","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2021.08.009_bib0022","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.nmd.2020.07.005","article-title":"Age and baseline values predict 12 and 24-month functional changes in type 2 SMA","volume":"30","author":"Coratti","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0023","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ana.25900","article-title":"Clinical variability in spinal muscular atrophy type III","volume":"88","author":"Coratti","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0024","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0026","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0027","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.24864","article-title":"Emerging therapies and challenges in spinal muscular atrophy","volume":"81","author":"Farrar","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0028","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1172\/JCI121658","article-title":"Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain","volume":"128","author":"Sumner","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2021.08.009_bib0029","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.nmd.2021.08.009_bib0030","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"key":"10.1016\/j.nmd.2021.08.009_bib0031","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2021.08.009_bib0032","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2021.08.009_bib0033","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0034","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0035","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2021.08.009_bib0036","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2021.08.009_bib0037","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.25533","article-title":"Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data","volume":"86","author":"Pane","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0038","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study","volume":"91","author":"Aragon-Gawinska","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.08.009_bib0039","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/JND-190441","article-title":"Treatment with nusinersen - Challenges regarding the indication for children with SMA type 1","volume":"7","author":"Pechmann","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2021.08.009_bib0040","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420907803","article-title":"Experiences from treating seven adult 5q spinal muscular atrophy patients with nusinersen","volume":"13","author":"Jochmann","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0041","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","article-title":"Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3","volume":"91","author":"Maggi","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2021.08.009_bib0042","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0043","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and treatment effects of nusinersen in longstanding adult 5q-SMA Type 3 - A prospective observational study","volume":"6","author":"Walter","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2021.08.009_bib0044","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jnc.14953","article-title":"Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy","volume":"153","author":"Kessler","year":"2020","journal-title":"J Neurochem"},{"key":"10.1016\/j.nmd.2021.08.009_bib0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JND-190453","article-title":"Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy","volume":"7","author":"Yeo","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2021.08.009_bib0046","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1007\/s00415-020-09847-8","article-title":"Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy","volume":"267","author":"Osmanovic","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0047","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00415-020-10223-9","article-title":"Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4","volume":"268","author":"De Wel","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0048","doi-asserted-by":"crossref","first-page":"11069","DOI":"10.1038\/s41598-020-68051-w","article-title":"Fatigue in adults with spinal muscular atrophy under treatment with nusinersen","volume":"10","author":"Kizina","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmd.2021.08.009_bib0049","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1212\/WNL.0000000000009914","article-title":"Nusinersen in adult patients with spinal muscular atrophy: observations from a single center","volume":"95","author":"Moshe-Lilie","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.08.009_bib0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nmd.2020.12.006","article-title":"Nusinersen treatment of older children and adults with spinal muscular atrophy","volume":"31","author":"Konersman","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0051","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JND-200551","article-title":"Real-world data from nusinersen treatment for patients with later-onset spinal muscular atrophy: a single center experience","volume":"8","author":"Mendonca","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2021.08.009_bib0052","doi-asserted-by":"crossref","unstructured":"Duong T., Wolford C., McDermott M.P., Macpherson C.E., Pasternak A., Glanzman A.M., et al. Nusinersen treatment in adults with spinal muscular atrophy. Neurology: Clinical Practice 2021: 10.1212\/CPJ.0000000000001033.","DOI":"10.1212\/CPJ.0000000000001033"},{"key":"10.1016\/j.nmd.2021.08.009_bib0053","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mus.26769","article-title":"Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience","volume":"61","author":"Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.08.009_bib0054","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejpn.2020.05.002","article-title":"Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: real world data from Hungarian patients","volume":"27","author":"Szabo","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0055","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study","volume":"15","author":"Audic","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2021.08.009_bib0056","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ppul.25142","article-title":"Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen","volume":"56","author":"Gomez-Garcia de la Banda","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0057","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.nmd.2021.03.012","article-title":"Age related treatment effect in type II spinal muscular atrophy pediatric patients treated with nusinersen","volume":"31","author":"Coratti","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0058","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/acn3.51411","article-title":"Nusinersen in pediatric and adult patients with type III spinal muscular atrophy","volume":"8","author":"Pera","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0059","doi-asserted-by":"crossref","first-page":"e00447","DOI":"10.1002\/prp2.447","article-title":"Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs","volume":"6","author":"Poirier","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.nmd.2021.08.009_bib0060","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.nmd.2021.08.009_bib0061","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0062","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.08.009_bib0063","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/dmcn.14412","article-title":"Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen","volume":"62","author":"Aragon-Gawinska","year":"2020","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0064","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany","volume":"5","author":"Pechmann","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2021.08.009_bib0065","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejpn.2017.11.001","article-title":"Single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1","volume":"22","author":"Pechmann","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0066","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/acn3.51276","article-title":"Type I SMA \"new natural history\": long-term data in nusinersen-treated patients","volume":"8","author":"Pane","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2021.08.009_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2019.12.047","article-title":"Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen","volume":"219","author":"Sansone","year":"2020","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2021.08.009_bib0068","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1164\/rccm.201906-1175LE","article-title":"Effect of nusinersen on respiratory muscle function in different subtypes of type 1 spinal muscular atrophy","volume":"200","author":"LoMauro","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nmd.2021.08.009_bib0069","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JND-200593","article-title":"Safety monitoring of gene therapy for spinal muscular atrophy with onasemnogene abeparvovec -A single centre experience","volume":"8","author":"Friese","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2021.08.009_bib0070","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jcsm.12542","article-title":"Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy","volume":"11","author":"Zhou","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.nmd.2021.08.009_bib0071","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.009_bib0072","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1038\/mtna.2016.47","article-title":"Altered levels of microRNA-9, -206, and -132 in spinal muscular atrophy and their response to antisense oligonucleotide therapy","volume":"5","author":"Catapano","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.nmd.2021.08.009_bib0073","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2021.08.009_bib0074","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JND-190468","article-title":"Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2","volume":"7","author":"Glascock","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2021.08.009_bib0075","doi-asserted-by":"crossref","first-page":"e33572","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"Crawford","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2021.08.009_bib0076","doi-asserted-by":"crossref","first-page":"e35462","DOI":"10.1371\/journal.pone.0035462","article-title":"Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study","volume":"7","author":"Finkel","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2021.08.009_bib0077","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/ejhg.2011.89","article-title":"Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability","volume":"19","author":"Also-Rallo","year":"2011","journal-title":"Eur J Hum Genet"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621006131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621006131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:11:47Z","timestamp":1760775107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896621006131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0960896621006131"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2021.08.009","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spinal muscular atrophy: from rags to riches","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2021.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}